Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom
- PMID: 32402996
- PMCID: PMC7182517
- DOI: 10.1016/j.thromres.2020.04.028
Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom
Conflict of interest statement
Declaration of competing interest WT – speaker's fees from Pfizer, Bayer and an advisory board for Daiichi Sanyo. MB – speakers fee STAGO, Advisory board Novartis, Cosmopharma, Werfen. KS -member of NICE NG 89 VTE guideline group and has received speaker's fees from Actelion. No other authors declared relevant conflicts of interest.
Figures
Comment in
-
Reply to: Liu C, et al. Intestinal microbiota dysbiosis play a role in pathogenesis of patients with primary immune thrombocytopenia.Thromb Res. 2020 Sep;193:77. doi: 10.1016/j.thromres.2020.06.006. Epub 2020 Jun 5. Thromb Res. 2020. PMID: 32526543 No abstract available.
-
Beware overestimation of thrombosis in ICU: Mortality is not the only competing risk!Thromb Res. 2020 Sep;193:78. doi: 10.1016/j.thromres.2020.05.019. Epub 2020 May 30. Thromb Res. 2020. PMID: 32526544 No abstract available.
Comment on
-
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10. Thromb Res. 2020. PMID: 32291094 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical